Dicerna Pharmaceuticals Inc
NASDAQ:DRNA
Market Cap (Intraday) | 1.96B |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | N/A |
50-Day MA | N/A |
200-Day MA | N/A |
Dicerna Pharmaceuticals, Inc. Stock, NASDAQ:DRNA
33 Hayden Avenue, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.621.8097
Number of Employees: 187
Description
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.